FDA approves new drug to treat hypoactive sexual desire disorder in premenopausal women

The U.S. Food and Drug Administration today approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Source: News Medical, https://www.news-medical.net/